Chronic Pain Treatment Market Estimated To Reach $168.99 Billion, Growing At 9.1% CAGR By 2030
What Is The Present Market Size Of The Chronic Pain Treatment Market, And At What Annual Growth Rate Is It Expanding?
The chronic pain treatment market size has grown strongly in recent years. It will grow from $109.05 billion in 2025 to $119.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to opioid usage, musculoskeletal disorders, aging population, hospital pain clinics, post-surgical pain management.
The chronic pain treatment market size is expected to see strong growth in the next few years. It will grow to $168.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to opioid regulation, device-based therapies, chronic disease prevalence, mental health integration, outpatient pain care growth. Major trends in the forecast period include shift toward non-opioid pain therapies, growth of neuromodulation devices, expansion of multidisciplinary pain management, increased focus on personalized pain care, integration of psychological support therapies.
Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24504&type=smp
What Fundamental Drivers Are Expected To Boost The Chronic Pain Treatment Market Throughout The Forecast Period?
The rising prevalence of arthritis pain is expected to propel the growth of the chronic pain treatment market going forward. Arthritis pain refers to the discomfort, aching, or soreness in the joints caused by inflammation or degeneration due to arthritis. The rising prevalence of arthritis pain is primarily driven by the aging population, as joint wear and tear naturally increase with age, leading to a greater incidence of arthritis-related conditions. Chronic pain treatment helps arthritis pain by targeting inflammation and nerve sensitivity to reduce discomfort, improve joint function, and enhance overall quality of life for individuals living with persistent arthritis symptoms. For instance, in July 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, an estimated 21.2% of adults aged 18 and older in the US were diagnosed with arthritis in 2023. Therefore, the rising prevalence of arthritis pain is driving the growth of the chronic pain treatment market.
What Are The Key Segmentation Components That Define The Structure Of The Chronic Pain Treatment Market?
The chronic pain treatment market covered in this report is segmented —
1) By Product Type: Drugs, Devices
2) By Indication: Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine, Fibromyalgia, Other Indications
3) By Distribution channels: Direct, Indirect
4) By End-User: Hospitals, Clinics, Nursing Homes, Research Centers And Universities, Other End-Users
Subsegments:
1) By Drugs: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants, Muscle Relaxants, Topical Analgesics, Other Pain Relief Medications
2) By Devices: Neuromodulation Devices, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Spinal Cord Stimulators, Peripheral Nerve Stimulators, Radiofrequency Ablation Devices, Implantable Drug Delivery Devices
What Influential Trends Are Gaining Momentum Within The Chronic Pain Treatment Market?
Major companies operating in the chronic pain treatment market are focusing on developing innovative solutions, such as closed-loop spinal cord stimulation (SCS) systems, to meet the rising demand for advanced non-opioid therapies, better long-term pain control and improved patient quality of life. Closed-loop SCS systems are implantable, rechargeable neurostimulators that continuously sense neural signals and automatically adjust electrical stimulation in real time, unlike traditional open-loop SCS devices that deliver preset and non-responsive output. For instance, in April 2024, Medtronic plc, an Ireland-based medical device company, received U.S. Food and Drug Administration (FDA) approval for the Inceptiv Neurostimulation System. The device is a compact rechargeable implant that uses sensing electrodes to monitor evoked neural responses and automatically adjust stimulation. It provides full-body 1.5T and 3T MRI access with impedance-independent sensing and is indicated for chronic, intractable trunk or limb pain. It is designed to deliver more consistent pain relief, better responder outcomes and improved comfort compared with traditional fixed-output SCS systems.
Who Are The Standout Companies Known For Innovation In The Chronic Pain Treatment Market?
Major companies operating in the chronic pain treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mallinckrodt plc, Nevro Corp.
Get Your In-Depth Chronic Pain Treatment Market Report Now:
https://www.thebusinessresearchcompany.com/report/epidural-catheter-global-market-report
Which Geographical Region Is Projected To Lead The Chronic Pain Treatment Market Throughout The Forecast Period?
North America was the largest region in the chronic pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310–496–7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment